TABLE 1.
Study population characteristicsa
| Demographic | Value for study subjects (n = 15) |
|---|---|
| Age [median (range)] (yrs) | 20 (19–25) |
| Gender [no. (%)] | |
| Female | 11 (73.3) |
| Male | 4 (26.7) |
| Ethnicity [no. (%)] | |
| Hispanic | 5 (33.3) |
| Race [no. (%)] | |
| White | 9 (60) |
| Black | 4 (26.7) |
| More than one race | 2 (13.3) |
| History of vaccination | |
| Age at first dose [median (IQR)] (yrs) | 4.3 (2.0–7.6) |
| 2 vaccine doses [no. (%)] | 13 (86.7) |
| Time since last dose [median (range)] [yrs] | 8.6 (0.1–19.6) |
a
All donors had received their first dose of Varivax before the age of 10 years, except one subject, who was 23 years old. Thirteen donors had received 2 vaccine doses. Median time between the last vaccination and specimen sampling was 8.6 years (IQR, 6.7 to 9.6 years). One donor received the last dose 41 days prior to specimen sampling.